tetano
Editor, Senior Moderator
Cureus
. 2022 Feb 27;14(2):e22658.
doi: 10.7759/cureus.22658. eCollection 2022 Feb.
Use of Sotrovimab in a Pregnant Patient With COVID-19 Infection
Isha Gupta[SUP] 1 2 3 [/SUP], Esther S Arguello Perez[SUP] 4 [/SUP]
Affiliations
Abstract
For individuals with mild-to-moderate coronavirus disease 2019 (COVID-19, caused by severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2]), monoclonal antibodies (MOABs) are known to prevent progression of the disease and hospitalization. Pregnant women, who are at an increased risk of severe COVID-19 infection, have been significantly underrepresented in studies for MOAB treatments, especially sotrovimab. Specifically, there has only been one case reported of a pregnant woman using sotrovimab successfully. We report a second such patient - an unvaccinated 21-year-old, COVID-19-positive, 16-week pregnant woman who was followed closely over the next 60 days post-MOAB infusion. We noted prevention in the progression of the disease and hospitalization without any fetal/pregnancy-related complications.
Keywords: coronavirus 2019; covid-19; monoclonal antibodies; monoclonal antibody; omicron; pregnancy; pregnant; sars-cov-2; sotrovimab.
. 2022 Feb 27;14(2):e22658.
doi: 10.7759/cureus.22658. eCollection 2022 Feb.
Use of Sotrovimab in a Pregnant Patient With COVID-19 Infection
Isha Gupta[SUP] 1 2 3 [/SUP], Esther S Arguello Perez[SUP] 4 [/SUP]
Affiliations
- PMID: 35371772
- PMCID: PMC8963925
- DOI: 10.7759/cureus.22658
Abstract
For individuals with mild-to-moderate coronavirus disease 2019 (COVID-19, caused by severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2]), monoclonal antibodies (MOABs) are known to prevent progression of the disease and hospitalization. Pregnant women, who are at an increased risk of severe COVID-19 infection, have been significantly underrepresented in studies for MOAB treatments, especially sotrovimab. Specifically, there has only been one case reported of a pregnant woman using sotrovimab successfully. We report a second such patient - an unvaccinated 21-year-old, COVID-19-positive, 16-week pregnant woman who was followed closely over the next 60 days post-MOAB infusion. We noted prevention in the progression of the disease and hospitalization without any fetal/pregnancy-related complications.
Keywords: coronavirus 2019; covid-19; monoclonal antibodies; monoclonal antibody; omicron; pregnancy; pregnant; sars-cov-2; sotrovimab.